Chordia Therapeutics Inc.
Chordia Therapeutics株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 190A
FY2024 (Aug 2025) · J-GAAP · parent-only (non-consolidated) Source: filing S100X63V
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2024 (Aug 2025) runs Sep 1, 2024 – Aug 31, 2025.
| Gross margin | —Not in the filing: revenue, gross profit / cost of sales |
|---|---|
| Operating margin | —Not in the filing: revenue |
| Net margin | —Not in the filing: revenue |
| Return on equity | -54.2%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -48.8% |
| Revenue growth (YoY) | —Not in the filing: revenue |
| EPS (basic) | −¥26.03 |
| EPS growth (YoY) | —Base is zero or negative |
| Current ratio | 10.92x |
| Equity ratio | 90.8% |
| Book value / share | ¥35.29 |
| Free cash flow | −¥1.8B |